

## Key Sanochemia Group Data

in T€

### Performance data

	Q1 2002/03	Q2 2002/03	Q3 2002/03	Q1-Q3 2002/03	Q1-Q3 2001/02	Change as %	2001/02
	Oct.02-Dec.02	Jan.03-Mar.03	Apr.03-Jun.03	Oct.02-Jun.03	Oct.01-Jun.02		
Sales revenues	3.518	3.290	4.292	11.100	13.766	-19%	18.325
<i>Human Pharmaceuticals</i>	2.487	2.682	2.834	8.003	8.089	-1%	10.865
<i>Synthesis</i>	1.031	608	1.458	3.097	5.674	-45%	7.449
<i>R&amp;D</i>	0	0	0	0	3	-100%	11
R&D result*	-1.793	-1.198	-1.043	-4.034	-1.861	-117%	-2.412
EBITDA	-1.543	-736	-1.158	-3.437	1.658	-	2.281
Depreciation / amortisation	-1.029	-1.033	-995	-3.057	-2.772	-10%	-3.862
EBIT	-2.572	-1.769	-2.153	-6.494	-1.114	-483%	-1.581
<i>Human Pharmaceuticals</i>	-999	-298	-1.257	-2.554	-1.859	-37%	-3.526
<i>Synthesis</i>	220	-272	146	94	2.606	-96%	4.357
<i>R&amp;D</i>	-1.793	-1.199	-1.043	-4.034	-1.861	-117%	-2.412
Financial result	1.743	593	311	2.647	2.007	32%	2.204
Pre-tax profit / loss	-829	-1.176	-1.843	-3.848	893	-	623
Net profit / loss for the year	-163	-887	-1.234	-2.284	1.268	-	654
Earnings / losses per share	-0,02	-0,09	-0,12	-0,22	0,12	-	0,06

### Structural data

	30.06.2003	30.06.2002	Change as %	2001/02
				30.09.2002
Balance sheet total	74.862	78.177	-4%	77.180
Fixed assets	15.265	13.803	11%	14.355
Intangible assets	17.246	17.843	-3%	18.081
Shareholders' equity	53.986	57.007	-5%	56.433
Equity ratio	72,1%	72,9%	-1%	73,1%

### IAS Cash flow

	Q1-Q3 2002/03	Q1-Q3 2001/02	Change as %	2001/02
	Oct.02-Jun.03	Oct.01-Jun.02		
Cash flow from operating activities	315	-533	-	-1.745
Cash flow from investment	1.945	-1.344	-	-3.204
Cash flow from financing	-295	3.651	-	6.761

\* Since R&D revenues have been included in R&D results for the first time in 2002-2003, the figures for the previous year have been adjusted accordingly.

Due to reclassifications on account of new IAS standards, certain figures may not correspond with those previously published.

Some minor changes may be due to rounding cumulative figures.